BR112022009042A2 - Combinações farmacêuticas, composições farmacêuticas, kits e métodos para tratar um câncer - Google Patents

Combinações farmacêuticas, composições farmacêuticas, kits e métodos para tratar um câncer

Info

Publication number
BR112022009042A2
BR112022009042A2 BR112022009042A BR112022009042A BR112022009042A2 BR 112022009042 A2 BR112022009042 A2 BR 112022009042A2 BR 112022009042 A BR112022009042 A BR 112022009042A BR 112022009042 A BR112022009042 A BR 112022009042A BR 112022009042 A2 BR112022009042 A2 BR 112022009042A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical
kits
methods
treat cancer
pharmaceutical compositions
Prior art date
Application number
BR112022009042A
Other languages
English (en)
Portuguese (pt)
Inventor
Zhang Juan
Original Assignee
Cstone Pharmaceuticals Suzhou Co Ltd
Cstone Pharmaceuticals Shanghai Co Ltd
Cstone Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cstone Pharmaceuticals Suzhou Co Ltd, Cstone Pharmaceuticals Shanghai Co Ltd, Cstone Pharmaceuticals filed Critical Cstone Pharmaceuticals Suzhou Co Ltd
Publication of BR112022009042A2 publication Critical patent/BR112022009042A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BR112022009042A 2019-11-11 2020-11-11 Combinações farmacêuticas, composições farmacêuticas, kits e métodos para tratar um câncer BR112022009042A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019117155 2019-11-11
PCT/CN2020/128083 WO2021093764A1 (en) 2019-11-11 2020-11-11 Pharmaceutical combination and use thereof

Publications (1)

Publication Number Publication Date
BR112022009042A2 true BR112022009042A2 (pt) 2022-10-11

Family

ID=75911807

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009042A BR112022009042A2 (pt) 2019-11-11 2020-11-11 Combinações farmacêuticas, composições farmacêuticas, kits e métodos para tratar um câncer

Country Status (11)

Country Link
US (1) US20220387417A1 (https=)
EP (1) EP4031179A4 (https=)
JP (1) JP2023500385A (https=)
KR (1) KR20220103961A (https=)
CN (1) CN114901309A (https=)
AU (1) AU2020383580A1 (https=)
BR (1) BR112022009042A2 (https=)
CA (1) CA3160526A1 (https=)
IL (1) IL292646A (https=)
MX (1) MX2022005034A (https=)
WO (1) WO2021093764A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4450616A3 (en) * 2016-09-21 2025-01-01 Cstone Pharmaceuticals The novel monoclonal antibodies to programmed death 1 (pd-1)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
KR20220019839A (ko) * 2013-10-08 2022-02-17 다이이찌 산쿄 가부시키가이샤 항 fgfr2 항체와 타제의 조합
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR102662228B1 (ko) * 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN106432501B (zh) * 2015-08-06 2021-07-30 基石药业 新型抗pd-l1抗体
WO2017020291A1 (en) * 2015-08-06 2017-02-09 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pd-l1 antibodies
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
EP4450616A3 (en) * 2016-09-21 2025-01-01 Cstone Pharmaceuticals The novel monoclonal antibodies to programmed death 1 (pd-1)
CN107840887B (zh) * 2016-09-21 2022-03-25 基石药业（苏州）有限公司 一种新的pd-1单克隆抗体
KR102655301B1 (ko) * 2017-04-06 2024-04-08 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
CN110536694A (zh) * 2017-04-20 2019-12-03 Atyr 医药公司 用于治疗肺部炎症的组合物和方法
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
CN108379591B (zh) * 2018-04-03 2022-03-29 深圳大学 免疫激动剂靶向化合物的合成及其应用
CN109731019B (zh) * 2019-03-07 2021-07-16 康赋葆(深圳)生物医药科技有限公司 一种具有化疗增效作用的组合物，包括组成、制备及应用
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法

Also Published As

Publication number Publication date
JP2023500385A (ja) 2023-01-05
CN114901309A (zh) 2022-08-12
AU2020383580A1 (en) 2022-05-12
US20220387417A1 (en) 2022-12-08
EP4031179A1 (en) 2022-07-27
CA3160526A1 (en) 2021-05-20
KR20220103961A (ko) 2022-07-25
IL292646A (en) 2022-07-01
WO2021093764A1 (en) 2021-05-20
MX2022005034A (es) 2022-05-16
EP4031179A4 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
CO2020016619A2 (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso
BR112018075166A2 (pt) derivados de carbonucleosídeo substituídos úteis como agentes anticâncer
MX2019002750A (es) Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer.
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2020000299A1 (es) Compuestos, composiciones y métodos.
CO2019014414A2 (es) Moléculas de anticuerpo que se unen a cd73 y usos de las mismas
DOP2019000266A (es) Inhibidores de pd-1/pd-l1
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
UY37272A (es) Piridinas sustituidas con heteroarilo y métodos de uso
NI201600144A (es) Derivados de quinoxalina utiles como moduladores del fgfr cinasa
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
CL2012001422A1 (es) Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX2020004678A (es) Uso de profarmacos de riluzol para tratar ataxias.
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
BR112016029024A2 (pt) conjugados e composições de texafirina-pt(iv) para uso na superação da resistência à platina
BR112015032526A2 (pt) composições anticaspa e métodos de uso das mesmas
EA202191631A1 (ru) Композиции, содержащие бактериальные штаммы
CO2022008817A2 (es) Macrociclos para uso en el tratamiento de enfermedades
CL2021002387A1 (es) Métodos para predecir el cáncer de próstata y usos de los mismos
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
BR112022009042A2 (pt) Combinações farmacêuticas, composições farmacêuticas, kits e métodos para tratar um câncer